Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Shuxia Wang · UNIVERSITY OF KENTUCKY · 2023 · $478,167 — Obesity is an independent risk factor for development of non-alcoholic fatty liver disease (NAFLD). With the epidemic burden of obesity and metabolic diseases, NAFLD occurrence is steadily rising, along with the need for therapeutic options of this disease. Preliminary data from rodent and human stu…
Brianna Leilani Bourgeois · LSU HEALTH SCIENCES CENTER · 2023 · $42,047 — Abstract The primary purpose of this Ruth L. Kirschstein NRSA F30 application is to provide the groundwork that will prepare the applicant for an academic medical career. Much of the applicant’s career development will come from work in High Priority HIV/AIDS comorbidity-related research, and she wi…
Suchismita Acharya · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2023 · $370,000 — Glaucoma is a neurodegenerative disease of the eye with an estimated prevalence of 80 million patients worldwide by 2020, at least 6 to 8 million becoming bilaterally blind. Elevated intraocular pressure (IOP) causing axonal degeneration of the optic nerve and progressive loss of retinal ganglion ce…
Devanand Sarkar · VIRGINIA COMMONWEALTH UNIVERSITY · 2023 · $598,687 — Summary Nonalcoholic steatohepatitis (NASH), the most common cause of chronic liver disease in the Western world and a major global health problem, leads to cirrhosis and hepatocellular carcinoma (HCC). The lack of an optimum therapy mandates better understanding of the molecular pathogenesis of NAS…
Jayanth Panyam · TEMPLE UNIV OF THE COMMONWEALTH · 2023 · $1 — Agonists of toll like receptors (TLRs) are promising anticancer vaccine adjuvants because of their ability to induce proinflammatory cytokines necessary to generate a robust immune response. However, currently available TLR agonists suffer from a number of limitations including self-regulatory immun…
MICHAEL L GROSS · WASHINGTON UNIVERSITY · 2023 · $465,693 — Project Summary Mass spectrometry (MS) based footprinting is emerging as a powerful means to answer biological questions about membrane proteins (MPs), which participate in almost all physiological processes and represent more than 60% of drug targets. This approach affords sufficient structural inf…
Renato Samuel Navarro · STANFORD UNIVERSITY · 2023 · $156,708 — PROJECT SUMMARY Myocardial infarction (MI) is a leading cause of cardiovascular disease and death. After an MI, limited regeneration occurs, and instead, inflammation and scarring cause the affected myocardial tissue to turn fibrotic and thin. This tissue remodeling results in abnormal tissue mechan…
Fang-Yi Su · GEORGIA INSTITUTE OF TECHNOLOGY · 2023 · $110,905 — Engineered T cells that express chimeric antigen receptors (CARs) have shown remarkable efficacy against hematological malignancies. However, broad implementation of CAR T cell therapies is limited by the lengthy (3–5 weeks) and costly ($350K–450K per treatment) ex vivo manufacturing pipeline. This …
Dewan Syed Fahmeed Hyder · YALE UNIVERSITY · 2023 · $251,250 — Project Summary Stroke is the leading cause of disability in the United States. Despite the effectiveness of thrombolysis and thrombectomy, outcomes after stroke remain poor and effective cerebroprotectant therapies are needed. This project will leverage the complementary expertise of a Stroke Neuro…
David Scott Johnson · GIGAMUNE, INC. · 2023 · $300,000 — PROJECT SUMMARY Project Title: In vivo Gene Delivery to Regulatory T Cells to Drastically Reduce the Cost of Regulatory T Cell Therapy Organization: GigaMune Inc. PI: David Johnson, Ph.D. Over 9,000 patients will receive liver transplants this year, and about 75% of those patients will survive at le…
Haitao Wang · MAYO CLINIC ROCHESTER · 2023 · $423,233 — PROJECT SUMMARY/ABSTRACT Heterotopic ossification (HO), a diverse pathologic process of formation of extraskeletal bone in muscle and soft tissues, can be classified into hereditary and nonhereditary (acquired) HO types. A rare and devastating form of hereditary HO is fibrodysplasia ossificans progr…
Guizhi Zhu · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2023 · $381,938 — Project Summary The objectives of this MIRA application are to 1) in vivo profiling of heterogeneous Adenosine deaminase acting on RNA (ADAR) using RNA nano-reporters as a tool to understand ADAR biology and guide the design of ADAR- based therapy; 2) promoting endogenous ADAR modulation using chime…
Olga Gursky · BOSTON UNIVERSITY MEDICAL CAMPUS · 2023 · $124,824 — Abstract Aberrant lipoprotein metabolism is a hallmark of obesity that affects >40% of Americans. Obesity and its com- plications, including type-2 diabetes (T2D), cardiovascular, amyloid and severe viral diseases, are the leading causes of premature death. The ultimate goal of this research is to …
Pranam Chatterjee · DUKE UNIVERSITY · 2023 · $331,981 — Summary Over 600 human proteins have been recently prioritized as key cancer targets, with nearly half being considered ‘intractable’ by standard small-molecule inhibition approaches, due to target instability and active site accessibility constraints. By redirecting the ubiquitin-proteasomal pathwa…
Hong Chen · BOSTON CHILDREN'S HOSPITAL · 2023 · $785,922 — PROJECT SUMMARY/ABSTRACT Atherosclerosis is the leading cause of life-threatening coronary heart disease, ischemic stroke, and peripheral arterial disease in the United States. Notably, dyslipidemia remains a major risk factor despite effective lipid- lowering therapies and prevention programs. This…
Kristofer S Fritz · MITOTHERAPEUTIX, LLC · 2023 · $273,918 — Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of …
Worapol Ngamcherdtrakul · PDX PHARMACEUTICALS, INC. · 2023 · $400,000 — Lung cancer is the leading cause of cancer mortality, exceeding deaths from colon, breast, and prostate cancers combined. Resistance to chemo and targeted therapy is very common. Radiation therapy (RT) remains a key treatment in about 60% of lung cancer patients. We seek to develop a novel nanothera…
Esma Alp · KALOCYTE, INC. · 2023 · $1,050,000 — Research Summary/Abstract ErythroMer (EM) is a novel biosynthetic blood substitute developed to address the critically unmet need for emergency transfusion in situations where the use of banked red blood cells (RBCs) are either not available or undesirable. EM is a self-assembled lipid-oligomeric hy…
Bryan L Copple · MICHIGAN STATE UNIVERSITY · 2023 · $497,939 — Modified Project Summary/Abstract Section The summary/abstract did not require alteration The leading cause of acute liver injury and acute liver failure in the United States is hepatotoxicity caused by overdose of the pain medication acetaminophen (APAP). Even with available treatments (i.e., N-a…
Howard E Gendelman · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2023 · $690,750 — ABSTRACT Mononuclear phagocytes (MP; monocytes, macrophages, dendritic cells. and microglia) serve as human immunodeficiency virus type one (HIV-1) reservoirs, sites of viral persistence and latency, and inducers of end- organ disease. All are commonly linked to HIV-1 pathobiology. However, the key …